Group 1 - The company, Shenlian Biopharmaceutical, announced the successful integration of self-assembling nanoparticle technology with circular mRNA technology to develop the world's first circular mRNA vaccine for swine fever, achieving significant progress [1] - The research results have been published in the internationally recognized immunology journal, "Frontiers in Immunology," indicating the credibility and scientific validation of the findings [1] - The new vaccine is expected to innovate in both antibody persistence and production cost, providing a novel solution for swine fever purification [1] Group 2 - The traditional swine fever E2 subunit vaccine has been crucial in swine fever purification due to its excellent biosafety characteristics and the ability to distinguish between infected and immune animals, but high production costs have limited its widespread application [1] - The company has developed a new generation of swine fever E2 glycoprotein vaccine using a self-built mRNA-LNP technology platform, which combines high immunogenicity with cost-effectiveness [1] - The research team compared different cationic lipid formulations in cmRNA-LNP preparations, finding that the AX4-LNP formulation induced superior cellular and humoral immunity compared to other cationic lipids [1] Group 3 - The study successfully constructed a modular cmRNA-LNP platform integrated with mi3 nanoparticles, overcoming the technical limitations of traditional subunit vaccines and achieving synergistic enhancement of humoral and cellular immunity [2] - This technology not only provides a new generation solution for the development of swine viral vaccines but also has the potential to be expanded to other animal disease vaccines [2]